VAXMED is an Australian, privately-owned biotechnology company developing novel vaccines for infectious diseases, based in Melbourne and Adelaide. We use complex computer algorithms to design and develop highly effective vaccines and a state-of-the-art production process. Our vaccines are fully synthetic and designed to provide long lasting immunity in a single shot vaccination and at the same time, broad-spectrum cover against multiple virus strains or infectious diseases. Our proprietary manufacturing technology is designed to produce 100s of millions of doses from each batch run in a matter of weeks. Unlike most other vaccines, VAXMED vaccines do not require consistent cold storage and temperature control from manufacture through to point of use. They can be stored at room temperature when freeze dried, many years. VAXMED’s vaccines and novel technology has been independently evaluated by leading global vaccine experts, both in industry and academia as one of the most promising in the field. The VAXMED product pipeline includes A universal influenza vaccine which will cover all seasonal strains, future pandemic strains without the need to reformulate the vaccine each season; Respiratory Syncytial Virus (RSV) a major cause of lower respiratory tract infections in children and the elderly worldwide; Dual Staphylococcus and Pseudomonas (ventilator-associated pneumonia, chronic pulmonary infection in cystic fibrosis patients, and burn and soft tissue infections); Universal Coronavirus, a vaccine protective against most Coronaviruses including COVID-19, the previous SARS virus, Middle Eastern Respiratory Syndrome (MERS), and other human Coronaviruses that cause common colds and potentially future outbreaks; African Swine Fever (AFS) which AFS is a major problem in Asia, Europe and Africa affecting the pig industry.